Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

NCT05515315 is registered in ClinicalTrials.gov with Fuzhou General Hospital as lead sponsor.

NCT NCT05515315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05515315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
Lead sponsor
Fuzhou General Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
May 31, 2022
Completion date
May 31, 2027
Enrollment
93 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunotherapy esophagus cancer